Trials / Completed
CompletedNCT00994760
Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years
A Prospective Non-interventional/Observational Patient Cohort Study on the Efficacy of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 131 (actual)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of the study was to evaluate the safety and efficacy of intranasal fentanyl spray in cancer patients over four weeks, especially during cancer-related breakthrough pain (BTP) attacks. The fentanyl spray was applied into the nose by a metered-spray device. The study was to provide further data on pharmacoeconomic efficiency of intranasal fentanyl spray.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Instanyl (Intranasal Fentanyl) | This was an observational study. Therefore, the physician decided about dosage according to individual needs. |
Timeline
- Start date
- 2009-09-01
- Primary completion
- 2010-09-01
- Completion
- 2010-11-01
- First posted
- 2009-10-14
- Last updated
- 2012-09-27
- Results posted
- 2012-09-27
Locations
168 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT00994760. Inclusion in this directory is not an endorsement.